Pioglitazone and bladder cancer: A propensity score matched cohort study.
Summary of "Pioglitazone and bladder cancer: A propensity score matched cohort study."
AIM:
To examine whether exposure to pioglitazone use is associated with increased incidence of bladder cancer in patients with type 2 diabetes mellitus.
METHODS:
A cohort study was done in the General Practice Research Database (GPRD) between 2001 and 2010. 207,714 patients aged ≥40 years with type 2 diabetes were studied (23,548 exposed to pioglitazone and 184,166 exposed to other antidiabetic medications but not pioglitazone). The association between pioglitazone and risk of bladder cancer was assessed by a Cox regression model. A propensity score matched analysis was done in a group of patients without missing baseline characteristics data.
RESULTS:
66 and 803 new cases of bladder cancer occurred in the pioglitazone and other group respectively (rates of 80.2 (95%CI 60.8-99.5) and 81.8 (95%CI 76.2-87.5) per 100,000 person-years respectively). Pioglitazone did not increase the risk of bladder cancer significantly compared with other antidiabetic drugs treatment group, (adjusted hazard ratio (HR), 1.16, 95%CI 0.83-1.62). In a matched propensity score analysis in which both groups had similar baseline characteristics (17,249 patients in each group), the adjusted HR was 1.22 (95% CI 0.80-1.84).
CONCLUSIONS:
The results suggest that pioglitazone may not be significantly associated with an increased risk of bladder cancer in patients with type 2 diabetes. © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Affiliation
Medicines Monitoring Unit (MEMO), Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK.
Journal Details
This article was published in the following journal.
Name: British journal of clinical pharmacology
ISSN: 1365-2125
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22574756
- DOI: http://dx.doi.org/10.1111/j.1365-2125.2012.04325.x
Medical and Biotech [MESH] Definitions
Matched-pair Analysis
A type of analysis in which subjects in a study group and a comparison group are made comparable with respect to extraneous factors by individually pairing study subjects with the comparison group subjects (e.g., age-matched controls).
Propensity Score
Conditional probability of exposure to a treatment given observed covariates.
Apgar Score
A method, developed by Dr. Virginia Apgar, to evaluate a newborn's adjustment to extrauterine life. Five items - heart rate, respiratory effort, muscle tone, reflex irritability, and color - are evaluated 60 seconds after birth and again five minutes later on a scale from 0-2, 0 being the lowest, 2 being normal. The five numbers are added for the Apgar score. A score of 0-3 represents severe distress, 4-7 indicates moderate distress, and a score of 7-10 predicts an absence of difficulty in adjusting to extrauterine life.
Cohort Effect
Variation in health status arising from different causal factors to which each birth cohort in a population is exposed as environment and society change.
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.
PubMed Articles
AIMS/HYPOTHESIS: Previous studies have suggested an increased risk of bladder cancer with pioglitazone exposure. We aimed to investigate the association between pioglitazone exposure and bladder cance...
Background The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes. In this study, we assessed the risk of bladder cancer associate...
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
OBJECTIVE: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bl...
BACKGROUND: The objective of this nationwide case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs). METHODS: A total of 606,583...
Bladder cancer: Pioglitazone increases risk of bladder cancer.
Clinical Trials
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time peri...
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
The purpose of this study is to evaluate the reproducibility of over active bladder symptom score (OABSS) in Asian countries.
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
The purpose of this study is to evaluate its reproducibility of overactive bladder symptom score (OABSS) and to evaluate its correlation to other measures of OAB symptoms.
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor af...
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent...
